US equities
|
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Merck & Co., Inc.
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial
July 02, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29
July 01, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season
June 26, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention
June 24, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)
June 23, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer
June 18, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
June 13, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
June 12, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
June 12, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
June 09, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia
June 09, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
June 04, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
May 31, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations
May 30, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial
May 30, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Third-Quarter 2025 Dividend
May 27, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
May 22, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
May 16, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers
May 15, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)
May 14, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Research on Novel Treatment Approaches and Scientific Advances From Merck’s Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025
May 13, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto
May 08, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the Bank of America 2025 Global Healthcare Conference
May 07, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware
April 29, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
April 27, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces First-Quarter 2025 Financial Results
April 24, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24
April 01, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA® (pembrolizumab) in Pivotal 3475A-D77 Trial
March 27, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
March 26, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
March 25, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
